<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000346</url>
  </required_header>
  <id_info>
    <org_study_id>AQ-PRO-013</org_study_id>
    <nct_id>NCT05000346</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms</brief_title>
  <acronym>SIROCCO-1</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel, Trial to Determine the Safety and Efficacy of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aquilon Pharmaceuticals S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aquilon Pharmaceuticals S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind parallel trial to assess the efficacy and safety of inhaled AQ001S in the&#xD;
      management of acute COVID-19 symptoms compared.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo-controlled, parallel clinical trial to determine the&#xD;
      safety and efficacy of inhaled AQ001S in the management of acute COVID-19 symptoms in adult&#xD;
      patients (≥ 18 years old) who are admitted to hospital due to the severity of his/her&#xD;
      confirmed or suspected COVID-19 disease. The patient will be treated for 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>During 28 days of treatment</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events as assessed by collection of (Serious) Adverse Events and general/local tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WHO clinical progression scale (COVID-19 clinical progression scale)</measure>
    <time_frame>At Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2 (Visit 5)</time_frame>
    <description>Change in the WHO clinical progression scale (reference: WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection, Lancet Infect Dis., Aug 2020, 20(8): e192-e197) with &quot;Uninfected&quot; as minimal value (e.g. 0) and &quot;Dead&quot; as maximal value (e.g. 10, worse outcome), ffrom baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to hospital discharge</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Time to hospital ldischarge measured over the treatment period from baseline (visit 2) to day 28 (visit 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Intensive Care Unit admission</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Time to Intensive Care Unit admission measured over the treatment period from baseline (visit 2) to day 28 (visit 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit stay</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Length of Intensive Care Unit stay measured over the treatment period from baseline (visit 2) to day 28 (visit 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospital readmission</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Time to hospital readmission measured over the treatment period from baseline (visit 2) to day 28 (visit 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital readmission</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Length of hospital readmission measured over the treatment period from baseline (visit 2) to day 28 (visit 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to mechanical ventilation</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Time to mechanical ventilation measured over the treatment period from baseline (visit 2) to day 28 (visit 5).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of death</measure>
    <time_frame>Within 60 days from hospitalisation</time_frame>
    <description>Occurence of death (all deaths).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Medical Research Council Dyspnea Scale</measure>
    <time_frame>to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2 (Visit 5)</time_frame>
    <description>Change in modified Medical Research Council Dyspnea (mMRC) Scale from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2 (Visit 5).&#xD;
Minimum mMRC Scale value is 0 (e.g. &quot;I only get breathless with strenuous exercise&quot;). The maximum mMRC Scale value is 4 (e.g. &quot;I am too breathless to leave the house&quot; or &quot;I am breathless when dressing&quot;, worse outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function measurement: Forced Expiratory Volume in the first second (FEV1)</measure>
    <time_frame>At Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2 (Visit 5)</time_frame>
    <description>Changes in FEV1 measured from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function measurement: Forced Vital Capacity (FVC)</measure>
    <time_frame>At Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2 (Visit 5)</time_frame>
    <description>Changes in FVC measured from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function measurement: FEV1/FVC ratio</measure>
    <time_frame>At Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2 (Visit 5)</time_frame>
    <description>Changes in FEV1/FVC ratio from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function measurement: Oxygen saturation (SpO2)</measure>
    <time_frame>At Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2 (Visit 5)</time_frame>
    <description>Changes in SpO2 measured from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function measurement: Fraction of inspired Oxygen (FiO2)</measure>
    <time_frame>At Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2 (Visit 5)</time_frame>
    <description>Changes in FiO2 measured from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function measurement: SpO2/FiO2 ratio</measure>
    <time_frame>At Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2 (Visit 5)</time_frame>
    <description>Changes in and SpO2/FiO2 ratio measured from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion Capacity for Carbon Monoxide measurements</measure>
    <time_frame>At Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2 (Visit 5)</time_frame>
    <description>Changes in the Diffusion Capacity for Carbon Monoxide (DLCO) from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary CT Scan</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in the pulmonary CT Scan between baseline (Visit 2) and Day 28±2 (Visit 5)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change immune system response</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in the immune system response will be measured from baseline (Visit 2) to Day 28±2 (Visit 5), using a 15-plex Human Cytokine Panel assay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in monocyte count</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in monocyte count will be measured from baseline (Visit 2) to Day 28±2 (Visit 5).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in lymphocyte count</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in lymphocyte count will be measured from baseline (Visit 2) to Day 28±2 (Visit 5).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in hyperinflammation biomarker: ferritin</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in hyperinflammation biomarkers will be measured from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in hyperinflammation biomarker: C reactive protein</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in hyperinflammation biomarkers will be measured from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in hyperinflammation biomarker: d-dimer</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in hyperinflammation biomarkers will be measured from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in hyperinflammation biomarker: soluble cluster of differentiation 40 ligand</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in hyperinflammation biomarkers will be measured from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in hyperinflammation biomarker: matrix metalloproteinase</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in hyperinflammation biomarkers will be measured from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in cardiovascular biomarker: troponin</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in troponin level will be measured from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in cardiovascular biomarker: creatine kinase</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes increatine kinase level will be measured from baseline (Visit 2) to Day 7±2 (Visit 3), Day 14±2 (Visit 4) and Day 28±2.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunology parameters: immunoglobulin E</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in immunoglobulin E rates from baseline (Visit 2) to Day 28±2 (Visit 5), and at each visit over the dosing period</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunology parameters: immunoglobulin A</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in immunoglobulin A rates from baseline (Visit 2) to Day 28±2 (Visit 5), and at each visit over the dosing period</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunology parameters: immunoglobulin G</measure>
    <time_frame>After 28 days of treatment</time_frame>
    <description>Changes in immunoglobulin G rates from baseline (Visit 2) to Day 28±2 (Visit 5), and at each visit over the dosing period</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Experimental AQ001S 0.125 mg/mL quarter in die</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AQ001S 0.125 mg/mL inhalation solution administered by inhalation 4 times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental AQ001S 0.125 mg/mL bis in die</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AQ001S 0.125 mg/mL inhalation solution administered by inhalation twice a day + placebo by inhalation twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator: placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No active drug - administered by inhalation 4 times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug, inhalation</intervention_name>
    <description>Solution administered by inhalation</description>
    <arm_group_label>Comparator: placebo</arm_group_label>
    <arm_group_label>Experimental AQ001S 0.125 mg/mL bis in die</arm_group_label>
    <arm_group_label>Experimental AQ001S 0.125 mg/mL quarter in die</arm_group_label>
    <other_name>inhaled drug, including placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient admitted to hospital due to the severity of his/her confirmed or suspected&#xD;
             COVID-19 disease.&#xD;
&#xD;
          2. Positive virus test for Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#xD;
             using real time polymerase chain reaction (nasal swab).&#xD;
&#xD;
          3. Patient with COVID-19 clinical progression scale score ≥ 4 (hospitalized; no oxygen&#xD;
             therapy).&#xD;
&#xD;
          4. Male or female, ≥18 years of age at the time of consent.&#xD;
&#xD;
          5. Patients who have given written informed consent.&#xD;
&#xD;
          6. Reliable patients who are willing to be available for the duration of the clinical&#xD;
             trial and willing to comply with clinical trial procedures.&#xD;
&#xD;
          7. Patients who have the ability to understand the requirements of the clinical trial.&#xD;
&#xD;
          8. Female patients of childbearing potential (women of childbearing potential, WOCBP )&#xD;
             should have a negative pregnancy test at Screening Visit.&#xD;
&#xD;
          9. Female patients of childbearing potential (women of childbearing potential, WOCBP1)&#xD;
             using a highly effective method of contraception (i.e., pregnancy rate of &lt; 1% per&#xD;
             year) on a stable regimen, for at least 28 days, and pursuing this contraception&#xD;
             during the trial and for 28 days after the last administration of the study drug The&#xD;
             highly effective methods of contraception must be one of the following: combined&#xD;
             estrogen and progestogen hormonal contraception with inhibition of ovulation,&#xD;
             progestogen-only hormonal contraception associated with inhibition of ovulation,&#xD;
             intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion,&#xD;
             vasectomized partner, or agreement on continuous abstinence from heterosexual&#xD;
             intercourse.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intensive care patients&#xD;
&#xD;
          2. Inability to use a nebulizer with a mouthpiece.&#xD;
&#xD;
          3. History of hypersensitivity to corticosteroid or to any of the excipients in the drug&#xD;
             preparation.&#xD;
&#xD;
          4. Untreated oral candidiasis.&#xD;
&#xD;
          5. Evidence of symptomatic chronic or acute respiratory infection other than COVID-19 in&#xD;
             the previous 8 weeks.&#xD;
&#xD;
          6. Proven diagnosis of Chronic Obstructive Pulmonary Disease, asthma or bronchiectasis.&#xD;
&#xD;
          7. Pulmonary malformations, tuberculosis, cystic fibrosis.&#xD;
&#xD;
          8. History or presence of severe renal (stage 4 (GFR = 15-29 mL/min)) and/or severe&#xD;
             hepatic impairment(s) (grade 4 or above)&#xD;
&#xD;
          9. Anticipated transfer to another hospital within 72 hours.&#xD;
&#xD;
         10. Use of inhaled corticosteroid, at a strength at least equivalent to 200 µg of&#xD;
             beclomethasone per day, within 7 days before Screening Visit.&#xD;
&#xD;
         11. Systemic corticosteroids (e.g., dexamethasone) within 28 days before Screening Visit.&#xD;
&#xD;
         12. Female patients who are breast-feeding, lactating, pregnant or intending to become&#xD;
             pregnant.&#xD;
&#xD;
         13. Any condition, including findings in the patients' medical history or in the&#xD;
             pre-randomization study assessments that, in the opinion of the Investigator,&#xD;
             constitute a risk or a contraindication for the participation of the patient into the&#xD;
             study or that could interfere with the study objectives, conduct or evaluation.&#xD;
&#xD;
         14. Current or previous participation in another clinical trial where the patient has&#xD;
             received a dose of an study drug containing small molecules within 30 days or 5&#xD;
             half-lives (whichever is longer) prior to entry into this study or containing&#xD;
             biologicals within 3 months prior to entry into this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Guiot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Liege</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maurizio Passanisi</last_name>
    <phone>+3242292809</phone>
    <email>mpassanisi@aquilonpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Julien Guiot, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

